-
New Clinical Trial Explores Combination Approach for Treatment-Resistant Prostate Cancer
The COSMYC Trial is testing whether combining testosterone with ZEN-3694, followed by enzalutamide plus ZEN-3694, can help shrink tumors in patients with castration-resistant prostate cancer.
-
HHS Signals Broader Access to Popular Wellness Peptides
The U.S. Department of Health and Human Services has indicated that certain wellness peptides will soon become more widely available, a move that could expand access for consumers interested in peptide-based wellness products.
-
HHS Draft Policy Signals Easier Access to Six Compounded Peptides
A new draft policy from the Department of Health and Human Services would ease enforcement restrictions on six compounded peptides, potentially expanding patient access through compounding pharmacies.
-
HHS Signals Expanded Access to Compounded Peptides
The Department of Health and Human Services is moving to allow pharmacies to compound certain peptides that currently lack FDA approval, potentially widening patient access to these therapies.
-
HHS Expands Access to Select Unapproved Peptides, Opening New Doors for Patients and Practitioners
Health Secretary Robert F. Kennedy Jr. has moved to broaden access to certain unapproved peptides, a shift that could expand options for patients and clinicians working with compounded peptide therapies.
-
Expanded Access: Pharmacies Permitted to Compound Popular Peptides
A new regulatory decision will allow pharmacies to compound certain popular peptides, potentially broadening patient access to these therapies. The move is being seen as a positive step for availability of personalized peptide treatments.
-
Longevity Expert David Sinclair Highlights Promising Peptides Backed by Emerging Science
Renowned longevity researcher David Sinclair suggests peptides may become as transformative for healthy aging as GLP-1 drugs were for weight loss, pointing to several compounds already gaining scientific attention.
-
Gilead’s $1.3B Bet on an Oral Peptide Signals Growing Confidence in Immunology Treatments
Gilead Sciences has agreed to pay $1.3 billion to acquire an oral peptide therapy aimed at immunology conditions, highlighting major pharmaceutical investment in peptide-based drug development.
-
Gilead Invests $1.3B in Promising Oral Peptide Therapy Targeting IL-23
Gilead has agreed to pay $1.3 billion upfront to license PepStar’s oral IL-23-targeting peptide, signaling strong confidence in oral peptide technology as an alternative to injectable biologics for inflammatory conditions.
-
New Pediatric Trial Launches to Test Sonrotoclax for Relapsed Childhood Leukemia
A new clinical trial is underway to evaluate sonrotoclax (BGB-11417) in children and adolescents with relapsed or refractory acute myeloid leukemia and B-cell acute lymphoblastic leukemia, offering a potential new option for young patients who need it most.